<DOC>
	<DOCNO>NCT02139358</DOCNO>
	<brief_summary>The purpose study evaluate safety activity gemcitabine plus trastuzumab pertuzumab patient metastatic human epidermal growth factor receptor 2 ( HER2 ) + breast cancer progress least one prior line chemotherapy plus HER2 target agent T-DM1 , trastuzumab , lapatinib .</brief_summary>
	<brief_title>Phase I/IIa Trial Gemcitabine Plus Trastuzumab Pertuzumab Previously Treated Metastatic HER2+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult male female ( age 18 old ) histologically confirm , metastatic human epidermal growth factor receptor 2 ( HER2 ) + ( immunohistochemistry ( IHC ) 3+ fluorescence situ hydridization ( FISH ) ratio ≥ 2.0 ) breast cancer Have progress least one prior line chemotherapy plus HER2 direct therapy trastuzumab and/or pertuzumab metastatic setting . TDM1 would count line therapy patient previously treat TDM1 eligible . Have treat gemcitabine metastatic set Measurable disease per Response Evaluation Solid Tumors ( RECIST ) 1.1 criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 2≤ Left Ventricular Ejection Fraction ( LVEF ) ≥ 50 % baseline determine either echocardiogram ( ECHO ) multiple gated acquisition scan ( MUGA ) Adequate bone marrow function indicate follow : absolute neutrophil count ( ANC ) &gt; 1500/µL ; Platelets ≥100,000/µL ; Hemoglobin &gt; 10 g/dL Adequate renal function , indicate creatinine ≤1.5x upper limit normal ( ULN ) Adequate liver function , indicate bilirubin ≤1.5x ULN , aspartic transaminase ( AST ) alanine transaminase ( ALT ) &lt; 2x ULN unless relate metastatic breast cancer liver ( case AST/ALT &lt; 5x ULN allow ) . Signed informed consent Adequate birth control sexually active woman childbearing potential Active uncontrolled infection major concurrent illness opinion investigator would render participant unsafe proceed study Uncontrolled central nervous system ( CNS ) metastases . Treated , nonprogressing CNS disease ( document brain magnetic resonance image [ MRI ] ) corticosteroids least 1 month potential participant eligible . Women pregnant lactate Prior chemotherapy within last 3 week ( last 6 week nitrosureas/mitomycin ) Prior radiation therapy within last 4 week ; prior radiation therapy indicator lesion ( unless objective disease recurrence progression within radiation portal document since completion radiation ) Other concomitant active malignancy History significant cardiac disease , cardiac risk factor uncontrolled arrhythmias Ejection fraction &lt; 50 % low limit institutional normal range , whichever low Hypersensitivity study medication Untreated psychiatric condition prevent informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast - Female</keyword>
	<keyword>Metastatic</keyword>
	<keyword>HER2+</keyword>
</DOC>